Proliferative activity (Ki-67 expression) and outcome in high grade osteosarcoma: A study of 27 cases

Sarcoma

Volumn 4, Issue 1-2, 2000, Pages 47-55

  Jong, Roland ^a   Davis, Aileen M ^a   Mendes, Maria G ^a   Wunder, Jay S ^a   Bell, Robert S ^a   Kandel, Rita ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Cell proliferation; MIB 1; Osteosarcoma; Prognosis

Indexed keywords

CISPLATIN; DOXORUBICIN; KI 67 ANTIGEN;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OSTEOSARCOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0033912827     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1155/S1357714X00000086     Document Type: Article

References (57)

1. 1 Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, Ayala A, Shuster J. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the multi-institutional osteosarcoma study. Clin Orthop Rel Res 1991;270:8-14.
2. 2 Glasser DB, Lane JM, Huvos AG, Marcove RC, Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma. Cancer 1992;69:698-708.
3. 3 Unni KK. Dahlin's Bone Tumors. General Aspects and Data on 11,087 Cases, 5th edn. Philadelphia: Lippincott-Raven, 1996:143-83.
4. 4 Petrilli AD, Gentil FC, Epelman S, Lopes LF, Bianchi A, Lopes A, De Assis Figueiredo MT, Marques E, De Bellis N, Consentino E, Prospero D, De Camargo OP, Oliveira NR, Franco E, Jaffe N. Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer 1991;68:733-37.
5. 5 Davis AM, Bell RS, Goodwin PJ. Prognostic factors in 'classical' osteosarcoma: a critical appraisal. J Clin Oncol 1994;12:423-31.
6. 6 Raymond AK, Chawla SP, Carrasco H, Ayala AG, Fanning CV, Grice B, Armen T, Plager C, Papadopoulos NEJ, Edeiken J, Wallace S, Jaffe N, Murray JA, Benjamin RS. Osteosarcoma chemotherapy effect: a prognostic factor. Sem Diagn Pathol 1987;4:212-36.
7. 7 Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 1990;2:275-80.
8. 8 Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992;11:121-39.
9. 9 Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
10. 10 Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
11. 11 Fan S, El-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ Jr., Magrath I, Kohn KW, O'Connor PM. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994;54:5824-30.
12. 12 Aas T, Børresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lønning PE. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine 1996;2:811-13.
13. 13 Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol 1999;187:127-37.
14. 14 Meikrantz W, Schlegel R. Apoptosis and the cell cycle. J Cell Biochem 1995;58:160-74.
15. 15 King KL, Cidlowski JA. Cell cycle and apoptosis: common pathways to life and death. J Cell Biochem 1995;58:175-80.
16. 16 Choong PFM, Akerman M, Willén H, Andersson C, Gustafson P, Alvegòrd T, Rydholm A. Expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in soft tissue sarcoma. Is prognostic significance histotype-specific? APMIS 1995;103:797-805.
17. 17 Jensen V, Sorensen FB, Bentzen SM, Ladekarl M, Nielsen OS, Keller J, Jensen OM. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistochemical study including 216 soft tissue sarcomas. Histopathology 1998;32:536-46.
18. 18 Heslin MJ, Cordon-Cardo C, Lewis JJ, Woodruff JM, Brennan MF. Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma. Cancer 1998;83:490-97.
19. 19 Kirkegaard LJ, DeRose PB, Yao B, Cohen C. Image cytometric measurement of nuclear proliferation markers (MIB-1, PCNA) in astrocytomas. Am J Clin Pathol 1998;109:69-74.
20. 20 Thor AD, Liu S, Moore DH II, Edgerton SM. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 1999;17:470-77.
21. 21 Elias JM. Immunohistopathology. A Practical Approach to Diagnosis, 5th edn. Chicago: ASCP Press, 1999:9.
22. 22 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Stat Assoc 1958;53:457-81.
23. 23 Layfield LJ, Saria EA, Berchuck A, Dodge RK, Thompson JK, Conlon DH, Kerns B-JM. Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis. J Surg Oncol 1997;66:230-37.
24. 24 Biesterfeld S, Kluppel D, Koch R, Schneider S, Steinhagen G, Mihalcea AM, Schroder W. Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus. A prospective follow-up study on breast cancer using antibodies against MIB-1, PCNA, ER and PR. J Pathol 1998;185:25-31.
25. 25 Minimo C, McCue PA, Pindzola A, Brennan J, Bibbo M. Role of computed quantitation of immunohistochemical staining of Ki-67 antigen in diagnosing ampullary lesions. Anal Quant Cytol Histol 1996;18:400-4.
26. 26 Caulet S, Lesty C, Raphael M, Binet JL, Diebold J. Quantitative study of Ki-67 antibody staining in non-Hodgkin's lymphomas using image analysis. Anal Quant Cytol Histol 1991;13:279-87.
27. 27 Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad H-D. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;138:867-73.
28. 28 Risio M. Methodological aspects of using immunohistochemical cell proliferation biomarkers in colorectal carcinoma chemoprevention. J Cell Biochem 1994;19:61-7.
29. 29 Hendricks JB, Wilkinson EJ. Quality control considerations for Ki-67 detection and quantitation in paraffin-embedded tissue. J Cell Biochem 1994;19:105-10.
30. 30 Dictor M, Ehinger M, Mertens F, Akervall J, Wennerberg J. Abnormal cell cycle regulation in malignancy. Am J Clin Pathol 1999;112:S40-S52.
31. 31 Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, Mihatsch MJ. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996;178:437-41.
32. 32 Valente G, Giusti U, Kerim S, Gabriele P, Motta M, Ragona R, Navone R, Palestro G. High prognostic impact of growth fraction parameters in advanced stage laryngeal squamous cell carcinoma. Oncol Rep 1999;6:289-93.
33. 33 Mochen C, Giardini R, Costa A, Silvestrini R. MIB-1 and S-phase cell fraction predict survival in non-Hodgkin's lymphomas. Cell Prolif 1997;30:37-47.
34. 34 Nawa G, Ueda T, Mori S, Yoshikawa H, Fukuda H, Ishiguro S, Funai H, Uchida A. Prognostic significance of Ki67 (MIB1) proliferation index and p53 overexpression in chondrosarcomas. Int J Cancer 1996;69:86-91.
35. 35 Sallinen PK, Haapasalo HK, Visakorpi T, Helen PT, Rantala IS, Isola JJ, Helin HJ. Prognostication of astro-cytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 1994;174:275-82.
36. 36 Shivji KK, Kenny MK, Wood RD. Proliferating cell nuclear antigen is required for DNA excision repair. Cell 1992;69:367-74.
37. 37 Woosley JT. Measuring cell proliferation. Arch Pathol Lab Med 1991;115:555-7.
38. 38 Hitchcock CL. Ki-67 staining as a means to simplify analysis of tumor cell proliferation. Am J Clin Pathol 1991;96:444-6.
39. 39 Rudolph P, Peters J, Lorenz D, Schmidt D, Parwaresch R. Correlation between mitotic and Ki-67 labeling indices in paraffin-embedded carcinoma specimens. Hum Pathol 1998;29:1216-22.
40. 40 Sahin AA, Ro JY, El-Naggar AK, Wilson PL, Teague K, Blick M, Ayala AG. Tumor proliferative fraction in solid malignant neoplasms. Am J Clin Pathol 1991;96:512-9.
41. 41 Linden MD, El-Naggar AK, Nathanson SD, Jacobson G, Zarbo RJ. Lack of correlation between flow cytometric and immunohistologic proliferation measurements of tumors. Mod Pathol 1996;9:682-9.
42. 42 Irazusta SP, Vassallo J, Magna LA, Metze K, Trevisan M. The value of PCNA and AgNOR staining in endoscopic biopsies of gastric mucosa. Pathol Res Prac 1998;194:33-9.
43. 43 Soomro IN, Whimster WF. Growth fraction in lung tumours determined by Ki67 immunostaining and comparison with AgNOR scores. J Pathol 1990;162:217-22.
44. 44 Ohno T, Tanaka T, Takeuchi S, Matsunaga T, Mori H. Nucleolar organizer regions in bone tumors. Clin Orthop Rel Res 1991;272:287-91.
45. 45 Park H-R, Park Y-K. Expression of p53 protein, PCNA, and Ki-67 in osteosarcomas of bone. J Korean Med Sci 1995;10:360-7.
46. 46 Scotlandi K, Serra M, Manara C, Maurici D, Benini S, Nini G, Campanacci M, Baldini N. Clinical relevance of Ki-67 expression in bone tumors. Cancer 1995;75:806-14.
47. 47 Molendini L, Benassi MS, Magagnoli G, Merli M, Sollazzo MR, Ragazzini P, Gamberi G, Ferrari C, Balladelli A, Bacchini P, Picci P. Prognostic significance of cyclin expression in human osteosarcoma. Int J Oncol 1998;12:1007-11.
48. 48 Jensen ML, Schumacher B, Jensen OM, Nielsen OS, Keller J. Extraskeletal osteosarcomas. A clinicopathologic study of 25 cases. Am J Surg Pathol 1998;22:588-94.
49. 49 Viberti L, Papotti M, Abbona GC, Celano A, Filosso PL, Bussolati G. Value of Ki-67 immunostaining in preoperative biopsies of carcinomas of the lung. Hum Pathol 1997;28:189-92.
50. 50 Bubendorf L, Tapia C, Gasser TC, Casella R, Grunder B, Moch H, Mihatsch MJ, Sauter G. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 1998;29:949-54.
51. 51 van Oijen MGCT, Medema RH, Slootweg PJ, Rijksen G. Positivity of the proliferation marker Ki-67 in noncycling cells. Am J Clin Pathol 1998;110:24-31.
52. 1 phase regulation in osteosarcoma. Int J Cancer 1997;74:518-22.
53. 53 Chan HSL, Grogan TM, Haddad G, Hipfner DR, Deeley RG, Cole SPC. Standardization of a single-cell assay for sensitive detection of multidrug resistance protein expression in normal and malignant cells in archival clinical samples. J Lab Clin Med 1997;130:297-306.
54. 54 Baldini N, Scotlandi K, Barbanti-Brodano B, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M, Serra M. Expression of p-glycoprotein in high-grade osteosarcoma in relation to clinical outcome. N Engl J Med 1995;333:1380-5.
55. 55 Radig K, Hackel C, Herting J, Oda Y, Mittler U, Neumann W, Roessner A. Expression of p-glycoprotein in high grade osteosarcomas with special emphasis on chondroblastic subtype. Gen Diagn Pathol 1996/ 97;142:139-45.
56. 56 Serra M, Maurici D, Scotlandi K, Barbanti-Brodano G, Manara MC, Benini S, Picci P, Bertoni F, Bacci G, Sottili S, Baldini N. Relationship between p-glycoprotein expression and p53 status in high-grade osteosarcoma. Int J Oncol 1999;14:301-307.
57. 57 AJCC Cancer Staging Manual, 5th edn. Bone. Philadelphia: Lippincott-Raven, 1997;144.